Skip to main content
Veterinary Medicines

Anthelmin Plus Flavour Tablets for dogs

Authorised
  • Febantel
  • Pyrantel embonate
  • Praziquantel

Product identification

Medicine name:
Anthelmin Plus Flavour Tablets for dogs
Anthelmin Plus Flavour Tablets for dogs
Active substance:
  • Febantel
  • Pyrantel embonate
  • Praziquantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Febantel
    150.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel embonate
    144.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AC55
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Package description:
  • OPA/Al/PVC-Al blister. Cardboard box containing 2 tablets.
  • OPA/Al/PVC-Al blister. Cardboard box containing 4 tablets.
  • OPA/Al/PVC-Al blister. Cardboard box containing 10 tablets.
  • OPA/Al/PVC-Al blister. Cardboard box containing 30 tablets.
  • OPA/Al/PVC-Al blister. Cardboard box containing 50 tablets.
  • OPA/Al/PVC-Al blister. Cardboard box containing 100 tablets.
  • OPA/Al/PVC-Al blister. Cardboard box containing 300 tablets.

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
  • Krka d.d. Novo Mesto
  • Krka-Farma d.o.o.
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA10774/033/001
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0538/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Finland
  • Italy
  • Netherlands
  • Portugal
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."